tiprankstipranks
Grand Pharma Secures Rights to Innovative Dry Eye Treatment
Company Announcements

Grand Pharma Secures Rights to Innovative Dry Eye Treatment

Grand Pharmaceutical Group Limited (HK:0512) has released an update.

Stay Ahead of the Market:

Grand Pharmaceutical Group Limited has secured exclusive rights to develop and commercialize OC-01, a groundbreaking nasal spray for dry eye treatment, in Greater China. This strategic agreement with Corxel Pharmaceuticals aims to enhance Grand Pharma’s ophthalmology portfolio with innovative products that offer a more effective and patient-friendly alternative to traditional eye drops. As dry eye syndrome becomes a growing health concern in China, this move positions Grand Pharma to capitalize on a significant market opportunity.

For further insights into HK:0512 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles